November is Pancreatic Cancer Awareness Month
JOIN WITH AACR TO FIND BETTER WAYS TO PREVENT AND TREAT PANCREATIC CANCER
Pancreatic cancer begins in the cells of the pancreas—an organ in the abdomen that lies behind the lower part of the stomach. The pancreas has two main functions. It makes enzymes that help with digestion, and it makes hormones, such as insulin, that control how our bodies store and use glucose—sugar that is the body’s main source of energy.
There are two forms of pancreatic cancer: exocrine pancreatic cancer, which accounts for approximately 95% of all cases, and endocrine or pancreatic neuroendocrine tumors, also called islet cell tumors.
Older age, smoking, being overweight, having diabetes, chronic pancreatitis, and certain hereditary conditions are risk factors for pancreatic cancer.
The National Cancer Institute estimates that 67,530 people are expected to be diagnosed with pancreatic cancer in the United States in 2026. Approximately 52,740 deaths are expected to occur. Pancreatic cancer is the third leading cause of cancer death in the United States.
A Landmark Year for Pancreatic Cancer Treatment
The year 2026 marked a major milestone in pancreatic cancer care with the approval by the U.S. Food and Drug Administration (FDA) of the first RAS inhibitor for the disease, representing the first new systemic treatment option approved for patients in a long time. Get more details on the drug and the field of RAS-targeted therapy on AACR’s blog Cancer Research Catalyst.
One person’s story
When she was diagnosed with stage 2B pancreatic cancer in 2019, Donna Gustafson was 65 and about to celebrate her 50th wedding anniversary. As part of a phase I clinical trial, she was the first patient to receive a personalized cancer vaccine called autogene cevumeran, which was created using information from Donna’s resected tumor to train her immune system to find and kill cancer cells.
Donna’s response to the vaccine was extraordinary. It has now been more than six years since her treatment. Donna has no evidence of disease, and her body continues to show a strong immune response. She hopes her experience will help others appreciate the lifesaving potential of therapeutic cancer vaccines. Read her story on the AACR Cancer Progress Report 2026.
More ON PANCREATIC Cancer
Researchers are investigating ways to use vaccines as a form of immunotherapy to prevent and treat cancer, including for certain challenging indications such as pancreatic cancer. Learn more about the current landscape of pancreatic cancer vaccines, including the latest breakthroughs and the clinical progress, on Cancer Research Catalyst.
A growing field of investigation is exploring the role of innervation in pancreatic cancer and the complex crosstalk between nerve cells and tumor cells. Read more on some of the latest research in this area on Cancer Research Catalyst.
The recently approved RAS inhibitor daraxonrasib meaningfully improves outcomes for people with pancreatic cancer. Read more about a patient’s experience in AACR’s patient magazine Cancer Today.
Long-term follow-up results from a phase I clinical trial evaluating a personalized mRNA vaccine to treat pancreatic cancer were reported at the AACR Annual Meeting 2026. Read more about the results on Cancer Research Catalyst.
How AACR Supports Pancreatic Cancer Research
Major Conference
The AACR will hold the Conference on Pancreatic Cancer on September 8-11, 2027, in Boston. The conference is held annually to explore the latest developments in pancreatic cancer research, spanning basic, translational, and clinical research areas.
At the 2026 conference, Kevan M. Shokat, PhD, FAACR, received the Stephenson Global Prize that recognizes achievements in pancreatic cancer research. Read about how his breakthrough discoveries paved the way for the development of RAS inhibitors on Cancer Research Catalyst.
Supporting Research
Pancreatic cancer is an important area of research for the AACR and its partners. Learn more about grant-supported research projects:
- The Lustgarten Foundation-AACR Career Development Awards for Pancreatic Cancer Research include two awards. In 2026, Sandra Misale, PhD, of Johns Hopkins University, received the award in honor of Ruth Bader Ginsburg, and Dig B. Mahat, PhD, of Columbia University, received the award in honor of John Robert Lewis. Misale’s research focuses on targeting HER2 in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), while Mahat’s work addresses certain immune cells that help pancreatic tumors avoid the immune response, with the goal of guiding new immunotherapy approaches for pancreatic cancer.
- The 2026 Mark Foundation-AACR-Lustgarten Foundation Early Detection Awards were presented to Nikolaos Sgourakis, PhD, of Children’s Hospital of Philadelphia and Brian Wolpin, MD, of Dana-Farber Cancer Institute. Sgourakis is developing engineered proteins for early detection of KRAS-driven cancers; Wolpin’s project aims to detect and intercept precancerous pancreatic lesions by combining mutant KRAS inhibition with molecular imaging.
- In 2025, Jaewon Lee, MD, from the University of North Carolina at Chapel Hill, received the AACR-Conquer Cancer Young Investigator Award for Translational Cancer Research for his project investigating liquid biopsy-based molecular subtyping of pancreatic cancers.
- In 2025, Ioannis Verginadis, PhD, was awarded the AACR-Novocure Cancer Research Grant in support of research investigating the therapeutic effect of combining tumor treating fields (TTFields), a noninvasive modality for cancer treatment, with radiation therapy and immunotherapy in preclinical PDAC models.
FOR MORE INFORMATION
For more information, please see our page on pancreatic cancer, which includes information on treatment and the different types of the disease.
